Sudeep Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹197 Cr +20.9% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
SP

Sudeep Pharma Ltd

Q4 FY26Pharmaceuticals & Biotechnology

Sudeep Pharma Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹182Cr
+15.2% YoY
+5.8% QoQ
Net profit
₹49Cr
+11.4% YoY
+2.1% QoQ
Margin
34%
−3 pp YoY
−1 pp QoQ
Price₹1,112
Market cap₹10.8K Cr
P/E59.3

The short version

Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28. FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals.

From Sudeep Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28.
  • Specialty Ingredients segment forecasted to continue similar growth as in the past 2-3 years, maintaining strong momentum.
  • Bisglycinate product category projected to become a sizable revenue contributor starting FY28.
  • With the greenfield facility operational, pharma food nutrition volumes have grown over 20%, expecting further growth with capacity expansion.
  • Battery materials volume is expected to scale up, with a fair assumption of selling around 2,500 metric tons in FY27.

2 more points from Sudeep Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sudeep Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Battery Materials Project at Dahej: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027. Total target capacity up to 100,000 metric tons with approx. INR 600 crores capex planned.
  • Greenfield Manufacturing Project: Focused on pharma, food, and nutrition verticals, enhancing capabilities for high-value mineral molecules like glycinate and gluconate. Internal production validation completed; customer qualification ongoing.
  • Capex in FY26: INR 127 crores (including INR 34 crores for SAM land, INR 80 crores Greenfield project, INR 13 crores maintenance).

2 more points from Sudeep Pharma Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Sudeep Pharma has a strong order book with ongoing commercial purchase orders, including approximately 700 metric tons for battery materials received recently.
  • The company is engaged with 42 global customers across the cathode, cell, EV, and ESS ecosystem; 22 at lab validation, 14 at pilot scale, and 6 at commercial validation.
  • For battery materials, customer engagement and qualification progress are encouraging, with active off-take discussions.
  • Specialty ingredients segment has good visibility with approvals from large global customers in encapsulation technology and infant nutrition premix categories.
  • The company expects the specialty ingredients segment to maintain its growth momentum in FY27.

2 more points from Sudeep Pharma Ltd's call on order book

Create a free account to keep reading this call

Sudeep Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Sudeep Pharma Ltd Q4 FY26 results — key figures

Sudeep Pharma Ltd Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue182158+15.2%172+5.8%
Operating profit (EBITDA)6359+6.8%60+5%
Operating margin34%37%-3 pp35%-1 pp
Profit before tax6358+8.6%62+1.6%
Net profit (PAT)4944+11.4%48+2.1%
EPS (₹)4.334.54-4.6%4.20+3.1%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹197 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Balaxi Pharma (Q4 FY26)

    Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY

  • Accretion Pharmaceuticals (Q4 FY26)

    45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks

  • Gujarat Themis Biosyn (Q4 FY26)

    . Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.

  • Aptus Pharma (Q4 FY26)

    The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sudeep Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sudeep Pharma Ltd Q4 FY26 results?

Pharma Food Nutrition (PFN) segment expected to grow faster than the 10% achieved in FY26 in both FY27 and FY28. FY27 is expected to mark an important inflection point with continued momentum in both pharma food nutrition and specialty ingredients verticals.

What is Sudeep Pharma Ltd share price analysis?

Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sudeep Pharma Ltd planning capital expenditure?

Battery Materials Project at Dahej: Phase 1 capacity of 25,000 metric tons yearly, commissioning by April 2027.

Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.